MedTrace Logo

IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements

NCT02414490 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2020-08-13

No results posted yet for this study

Summary

This is a prospective observational study of 30 adult CIDP patients who receive home IVIg infusion services from AxelaCare Health Solutions, LLC. The decision to treat with IVIg will be entirely at the discretion of the patient's treating physician.

Conditions

Interventions

DRUG

Intravenous Immunoglobulin

The decision to treat with IVIg will be entirely at the discretion of the patient's treating physician.

Sponsors & Collaborators

  • BriovaRx Infusion Services

    collaborator INDUSTRY

  • CSL Behring

    collaborator INDUSTRY

  • University of Minnesota

    lead OTHER

Principal Investigators

  • Jeffrey A Allen, MD · University of Minnesota

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2019-05-31
Completion
2020-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02414490 on ClinicalTrials.gov